{Reference Type}: Journal Article
{Title}: COX-2 Overexpression in Schneiderian Papillomas.
{Author}: Suh JD;Hur K;Ference EH;Lam DD;Fong A;Correa AJ;Wrobel B;
{Journal}: Allergy Rhinol (Providence)
{Volume}: 11
{Issue}: 0
{Year}: Jan-Dec 2020
暂无{DOI}: 10.1177/2152656720973689
{Abstract}: <B>UNASSIGNED: </B>Schneiderian papillomas (SP) are aggressive sinonasal tumors that occasionally extend into areas that are surgically unresectable.<BR><B>UNASSIGNED: </B>evaluate the signifcance of cyclo-oxygenase-2 (COX-2) expression in SP.<BR><B>UNASSIGNED: </B>Immunohistochemistry for COX-2 was performed on SP samples and middle turbinates from chronic rhinosinusitis without nasal polyps controls obtained during surgical resection between 2009-2017. A positive stain was defined as having 10% or more cells exhibiting diffuse immunoreactivity. Comparisons were performed using Fisher Exact tests, t-tests, and ANOVA.<BR><B>UNASSIGNED: </B>The study included 67 tumor samples and 9 controls from two academic institutions. The mean age of the SP group was 55.4 years and 53.2 years in the control group (p = 0.71). Thirty-nine (58.2%) SP patients had previous surgery compared to 1 (11.1%) in the control group (p = 0.01). The most common tumor attachment sites were the maxillary (47.8%) and ethmoid (25.4%) sinuses. Fifteen (22.4%) SP samples stained strongly positive for COX-2 and 24 (35.8%) stained weakly positive compared to no positive stains in the control group (p < 0.01). When stratified by COX-2 intensity, there were no statistically significant differences in gender, smoking history, history of previous sinus surgery, site of attachment, papilloma subtype, or future recurrence between SP samples.<BR><B>UNASSIGNED: </B>COX-2 was overexpressed in 58.2% of SP cases, and strongly positive in 22.4% of cases, compared to no positive staining among controls. No significant differences in COX-2 expression were observed between SP subtypes or recurrent tumors. Further studies are warranted to evaluate COX-2 as a possible therapeutic target in tumors that overexpress the enzyme.